Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | HPGD | P15428 | 6/20 | 0.43 |
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 2/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28472884 | 0.86 | TLR8 (0.41) | ALDH1A1KDM4EHPGDGAASMN1; SMN2 | |
| SCHEMBL28468125 | 0.84 | LOXL2 (0.46) | ALDH1A1KDM4EHPGDGAASMN1; SMN2 | |
| SCHEMBL27272748 | 0.84 | SLC22A12 (0.44) | ALDH1A1KDM4EHPGDGAASMN1; SMN2 | |
| SCHEMBL7656202 | 0.84 | KDM4E (0.38) | ALDH1A1KDM4EHPGDGAASMN1; SMN2 | |
| SCHEMBL7655673 | 0.83 | LMNA (0.47) | ALDH1A1KDM4EHPGDGAASMN1; SMN2 | |
| SCHEMBL12090340 | 0.82 | DYRK1A (0.48) | ALDH1A1KDM4EHPGDGAAHTT | |
| SCHEMBL8682731 | 0.82 | KDM4E (0.39) | ALDH1A1KDM4EHPGDGAASMN1; SMN2 | |
| SCHEMBL7658111 | 0.80 | KDM4E (0.37) | ALDH1A1KDM4EHPGDGAASMN1; SMN2 | |
| SCHEMBL23559707 | 0.77 | ADORA2A (0.47) | ALDH1A1KDM4EHPGDGAASMN1; SMN2 | |
| SCHEMBL30987632 | 0.77 | ALDH1A1 (0.44) | ALDH1A1KDM4EHPGDGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6489333-B2 | HETEROCYCLIC COMPOUNDS CONTAINING A GUANIDINE MIMIC, FOR INHIBITION OF CELL ADHESION, TREATMENT OF ANGIOGENESIS DISORDERS, INFLAMMATION, CANCER METASTASIS, DIABETIC RETINOPATHY, THROMBOSIS, RESTENOSIS, MACULAR DEGENERATION | BRISTOL - MEYERS SQUIBB PHARMA COMPANY | 2002-12-03 | — | — | US | disclosed |
| US-20010044535-A1 | Integrin antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044535-A1 | Integrin antagonists | ITGB3, VCAM1, ITGB2 | ALDH1A1 2216/4885KDM4E 3935/4885HPGD 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.